Oxidative stress and response in relation to coronary artery disease in type 1 diabetes

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3503-3509

  Costacou, Tina ^a   Evans, Rhobert W ^a   Schafer, Gerald L ^a   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; GAMMA TOCOPHEROL; ISOPROSTANE DERIVATIVE; 15-F2T-ISOPROSTANE; BIOLOGICAL MARKER; CREATININE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; URINE LEVEL; VITAMIN BLOOD LEVEL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; PATHOPHYSIOLOGY; URINE; YOUNG ADULT;

ADULT; ALPHA-TOCOPHEROL; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CREATININE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INCIDENCE; ISOPROSTANES; MALE; OXIDATIVE STRESS; YOUNG ADULT;

EID: 84891878365     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2378     Document Type: Article

References (42)

1. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26: 1034-1053
2. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9
3. Roberts LJ,Morrow JD.Measurement of F (2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28:505-513
4. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington, DC, National Academy Press, 2000
5. Willcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies.AmJ Cardiol 2008;101(10A):75D-86D
6. Costacou T, Zgibor JC, Evans RW, Tyurina YY, Kagan VE, Orchard TJ. Antioxidants and coronary artery disease among individuals with type 1 diabetes: Findings from the Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2006;20:387-394
7. The hypertension detection and followup program: hypertension detection and follow-up program cooperative group. Prev Med 1976;5:207-215
8. Warnick GR, Albers JJ. HeparindMn2+ quantitation of high-density- lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978;24: 900-904
9. Allain CC, Poon LS, Chan CSG, Richmond W,Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20: 470-475
10. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem1973;19:476-482
11. Ellis D, Buffone GJ. New approach to evaluation of proteinuric states. Clin Chem 1977;23:666-670
12. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
13. Driskell WJ, Neese JW, Bryant CC, Bashor MM. Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography. J Chromatogr A 1982;231:439-444
14. Miller KW, Lorr NA, Yang CS. Simultaneous determination of plasma retinol, alphatocopherol, lycopene, alpha-carotene, and beta-carotene by high-performance liquid chromatography. Anal Biochem 1984;138: 340-345
15. Evans RW, Shaten BJ, Day BW, Kuller LH. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am J Epidemiol 1998; 147:180-186
16. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41:924-927
17. Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: implications for atherosclerosis. Free Radic Biol Med 2000;28:1795-1805
18. Pizer SM. Numerical Computing and Mathematical Analysis. Pizer SM, Ed. Chicago, IL, Science Research Associates, Inc., 1975
19. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-2023
20. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-786
21. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebocontrolled trial. Lancet 2000;356:1213-1218
22. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715-1720
23. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455
24. Levy AP, Gerstein HC, Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767
25. MilmanU, BlumS, Shapira C, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28: 341-347
26. BlumS, Vardi M, Levy NS,Miller-Lotan R, Levy AP. The effect of vitamin E supplementationoncardiovascular riskindiabetic individuals with different haptoglobin phenotypes. Atherosclerosis 2010;211: 25-27
27. Costacou T, Orchard TJ. Adiponectin: good, bad, or just plain ugly? Kidney Int 2008;74: 549-551
28. TraberMG, Arai H. Molecular mechanisms of vitamin E transport. Annu Rev Nutr 1999;19:343-355
29. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-366
30. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-9387
31. Helmersson J, Basu S. F(2)-isoprostane and prostaglandin F(2 alpha)metabolite excretion rate and day to day variation in healthy humans. Prostaglandins Leukot Essent Fatty Acids 2001;65:99-102
32. Keaney JF Jr, Larson MG, Vasan RS, et al.; Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23: 434-439
33. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: amatched case-control study. Circulation 2004;109:843-848
34. Polidori MC, Praticó D, Parente B, et al. Elevated lipid peroxidation biomarkers and lowantioxidant status in atherosclerotic patients with increased carotid or iliofemoral intima media thickness. J Investig Med 2007;55:163-167
35. ShishehborMH, Zhang R,Medina H, et al. Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 2006; 41:1678-1683
36. Basarici I, Altekin RE, Demir I, Yilmaz H. Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coron Artery Dis 2007;18:615-620
37. RoestM, Voorbij HA, Van der Schouw YT, Peeters PH, Teerlink T, Scheffer PG. High levels of urinary F2-isoprostanes predict cardiovascular mortality in postmenopausal women. J Clin Lipidol 2008;2:298-303
38. Flores L, Rodela S, Abian J, Clària J, Esmatjes E. F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism 2004;53:1118-1120
39. Nieto FJ, Iribarren C, GrossMD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 2000;148:131-139
40. Nojiri S, Daida H, Mokuno H, et al. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Jpn Heart J 2001;42:677-690
41. Valabhji J, McColl AJ, Richmond W, SchachterM, RubensMB, Elkeles RS. Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care 2001;24:1608-1613
42. Woo J, Leung SS, Lam CW, Ho SC, Lam TH, Janus ED. Plasma total antioxidant capacity in an adult Hong Kong Chinese population. Clin Biochem 1997;30:553-557